What does it take to get investors on board? Welcome back to Inside the Investor Mindset — our interview series uncovering how investment decisions are made, what makes a startup stand out, and what it takes to turn scientific potential into an opportunity investors believe in.
Much of the money in Biotech now follows a simple rule: wait until the science has been de-risked, then invest. Once a company has a development candidate and a reasonably clear path into the clinic, there is a substantial pool of capital ready for it in Europe and the US. Before that point, when the open question is whether a piece of biology can become a medicine at all, the field thins out considerably.
4BIO Capital has made that earlier, less crowded stage its territory. The London-based venture firm invests in advanced therapies — including cell and gene therapies, RNA-based therapies, targeted therapies and the microbiome — and backs companies developing treatments for areas of high unmet medical need, often at an early stage.
Owen Smith, a partner at 4BIO Capital, began his career in the life sciences before qualifying as a chartered accountant and moving into venture capital in 2014.
In conversation with NXTin Health, he explains how 4BIO separates scientific uncertainty from avoidable risk, why Europe’s gap with the US is no longer simply a question of money, what Japan and Texas are doing that the UK could learn from, and why, in his view, approval is not the end of a medicine’s journey.
4BIO has a reputation for taking on projects others might call “mission impossible”, and for backing companies that many European investors, often seen as conservative, would consider too risky. How do you assess those opportunities?
One thing I’d say first: we invest globally, and I would push back slightly on the idea that conservatism, or discomfort with risk, is a specifically European problem. I think it’s more about stage than geography.
Globally, once a Biotech has a development candidate and a reasonably clear path into the clinic, there’s a substantial pool of capital, both in Europe and the US. I always include the UK in Europe — I’m one of those people who holds on to the past. Financing development is much more comfortable once you have that candidate.
Before that point, though, there is nervousness, and capital is a lot scarcer. That’s where there is still genuine scientific uncertainty, and a lot of the market, in Europe and the US, has moved towards development risk and away from discovery risk. In my experience, established investors are relatively comfortable asking whether a molecule will work in patients and whether there’s a team in place capable of running that study. Fewer and fewer groups are comfortable answering the question: can this biology be turned into a medicine at all?
That’s a perfectly rational choice for many funds, given their size, their return requirements and the timelines they’re working to. But someone needs to take the early risk. Otherwise, there’s nothing for the other groups, whether in Europe or the US, to develop.
Being in the UK matters here. If we want the UK to be an extraordinary source of academic science, there needs to be money here, and people prepared to take that risk and build companies around it. I’m really fortunate to work with a group of like-minded people at 4BIO who deliberately spend a significant amount of our time looking to be that first institutional investor. We’re comfortable underwriting scientific uncertainty where we think the biology is compelling, where there’s a real unmet need that the technology addresses, and where we can identify the experiments that will resolve the key risk, so that other groups come in with enough capital to answer it.
Comfortable with scientific uncertainty, then — but not with everything. Where do you draw the line?
That’s not to say we’ll invest in anything that’s crazy. We try very hard not to underwrite what we see as avoidable risk. We don’t invest in black-box thinking. We’re very keen to put the right people around projects and to make sure there’s a clear path to approval. We want to map things out before we invest, and as a group we typically do. I’d say we’re very rational in how we engineer and build businesses.
But to come back to your point about Europe’s risk problem: I think there is a venture risk problem at the moment. And in the long term, someone has to take the biological risk, otherwise there’s nothing left for people to develop. That’s where we’ve been, and we have a consistent commitment to early-stage company creation as well as later Series A investing.
Founders sometimes suspect that the science matters less in a pitch than the team and how the story is told. Is that a myth, or does the team really carry the decision?
Ultimately, if you have poor science and a great team, it’ll fail. If you have great science and a poor team, it can fail. You need great science and great people to move things forward. So, I wouldn’t say there’s any one reason why Biotechs don’t get funded.
There’s a huge information asymmetry between the Biotechs being formed and the rest of the world. For better or worse, we’re in the privileged position of having somewhat better information, thanks to the people who come to pitch to us. So we’re often able to take a view on what else is in development and how it stacks up, understand whether there are near-term competitors, and think a lot about the later-stage picture, because we’ve built a number of businesses across a number of areas. My short answer is: you need great science and you need great people.
Government support can decide whether a country’s health innovation thrives or stagnates. Why does it so often struggle to keep pace with the science?
You’re throwing tactical nuclear penguins at me now. I like it. Let me start with what’s working, because here, in London, there is a lot that is working. In the UK, post-Brexit, when UK funds lost access to EIF funding, the British Business Bank really stepped up and has become an important backer, both of life science investors and, increasingly, directly of growth companies. So, the government has acted here.
My experience is also that ministers are visibly engaged with the sector. I think the MHRA has done a good job of adapting to its expanded role after Brexit. A lot has gone well in the UK to help it remain innovative.
I’d tweak your question slightly, though. My view is that government shouldn’t try to keep pace with scientists by predicting what’s going to win. Innovation will always be driven by sector specialists, whether that’s academics, an existing Biotech or a pharma company: people who have spent most of their careers understanding the biology, understanding patients and understanding how to take things through to approval. Governments should be creating conditions that say: if you have great science, it can become a great medicine.
How close is the UK to having those conditions in place?
We have good research funding for academic institutions. We now have a more effective regulator in the MHRA than we did. There’s clinical infrastructure that seems to work. There’s access to capital. For me, the big thing is that we need more continuity. We have most of the individual ingredients, but they need to work together more coherently.
I don’t think there’s great connectivity between academia and industry here in the UK. I question how many academics think beyond academia and about whether their work needs to be commercialised. Similarly, I don’t know how many entrepreneurs go looking into academia. We spend a lot of time doing that ourselves, and it’s quite surprising how often tech transfer officers tell us they haven’t seen anyone for a very long time. We need to find a way to take that excellent science more coherently through company formation to development and adoption.

And that last step — getting new medicines paid for and to patients?
That’s the one thing that will remain difficult in the UK, and it’s not a UK problem alone. The last step, adoption, is going to be hard. The NHS and public finances are under a lot of pressure, and paying for new medicines is hard. We have some amazing new tools, but the upfront cost is pretty high for medicines whose benefit accrues over the following five to 10 years.
I think the UK could be an unusually good place to innovate on that. We’ve used population-based payment models in the past, for hepatitis C and for antibiotics, and I’m hoping that in time there’ll be an equally imaginative approach to genetic medicines, where a payment covers a set number of patients over a year.
The UK has the ingredients in place. What I’d love to be able to say, to make the UK more attractive, is: you can develop your medicines here, you can build your Biotech here, and if you take it across the line, you’ll get it paid for. It’s something of a travesty when we see UK launches delayed relative to other countries. And again, it’s not only a UK issue. I’ve read some really good articles by peers on the continent describing similar challenges, with medicines discovered and developed in their own countries that weren’t yet available in the countries where they were developed, even though patients could access them elsewhere.
That sounds like a wider European pattern. From your experience, how do countries differ in the way they fund start-ups and scale-ups?
The UK is a great place to start a Biotech. It’s not perfect; nowhere is. For better or worse, in Europe we’ll always ask how we compare with the US, and the biggest difference with the US isn’t simply the amount of money. I think it’s partly cultural.
In the US it’s entirely normal for an academic scientist to imagine that their discovery could be a company — and entirely normal to imagine that each of their different discoveries could be a company. There’s a widely shared understanding that research doesn’t become medicine on its own. It has to move through translation, company formation and investment, and into the clinic. Then there’s a whole lot that happens towards the end, which even we’re not experts in and which very often involves a pharma partner.
There’s also an acceptance that it’s okay if it doesn’t work. You’ll do it a number of times; some will work, some won’t. There’s no shame in forming a business and seeing it fail. Historically, the UK and Europe have been more ambivalent about that journey — sometimes almost scared of it, because it doesn’t happen every day.
So founders end up putting a great deal of pressure on themselves?
And on colleagues. When a company is formed, it becomes a big thing. If it doesn’t go well, people remember it, and you can almost get stuck in a negative cycle. But I think that’s changing. In the UK, and in Europe too, we now have a critical mass of specialist investors and a lot of people who’ve been through a number of cycles.
With any founder I work with, I’m very clear from the outset: I’m okay if what we do fails on the biology. I’m really annoyed if it fails because we did something wrong — we ran the wrong clinical study, had the wrong people in place, got the financing strategy wrong or picked the wrong indication. Things within our control, I get annoyed about if they go wrong. If the biology fails, that’s tough. We can’t see biology. We can’t kick biology. Most of the time we’re testing a hypothesis, and if it doesn’t read out the way we want, that’s okay.
I think we’re getting better at saying that in the UK. If something fails on the biology, that person’s entire worth isn’t suddenly zero. There are lots of people who have had both successes and failures and have been through many cycles.
Beyond private venture capital, are there public funding models elsewhere that you think work particularly well?
There are lots of different models being tested. I’ll give a shout-out to a few, because we’ve either benefited from them or looked at them with real interest. Japan has its AMED funding, which combines specialist venture investment with matched non-dilutive funding from the government to move programmes forward. The message is: we want you to run your studies here, we want scientists to come here. I think that’s a really interesting model for a country pitching itself in a very similar way to the UK. It’s potentially quite transformative, and it has helped draw Biotechs from around the world to Japan.
Similarly, Texas has built CPRIT, the Cancer Prevention and Research Institute of Texas, to bring biotechs, expertise and people into the state to run studies through Houston, home to the largest medical district in the world, or through Dallas. It provides large non-dilutive funding to run clinical studies. At a time when fewer and fewer investors are available to fund early-stage studies, those schemes do move the needle, and I’m seeing European and US Biotechs look at them as viable options.
Everyone is also aware that Australia has a highly competitive research and development tax incentive, which is valuable for early-stage Biotechs with a first-in-human study that makes sense to run there. Given the size of Australia’s population, the challenge will always be access to the right patients and having the right expertise to run the study. Singapore, too, has started looking at ways to work along the lines of the AMED model.
And where does that leave the UK and Europe?
The UK is home. It’s never going to be simply about money; there will always be richer countries that can throw more money at biotech. What we need to keep doing is building successful biotechs. We need universities to stand on their own two feet, and we need to go through enough cycles of repeatedly turning ideas into companies, and companies into acquired businesses, sticking with them when it gets difficult.
We do a great job of attracting international capital. More to the point, we’re seeing more of that international capital set up local offices here in Europe, and that helps. It’s always good to have not just the biotech, but also the financing, in the right postcode.
To me, Europe is getting better. I feel much more comfortable now than I did five or ten years ago saying we should start a Biotech in the UK and build it here. More and more experienced scientists, executives and investors, and a track record of success, make people more comfortable building companies here in the UK and Europe, rather than keeping a small outpost here and moving the rest to Boston.
A familiar pattern is that companies do their science in Europe, raise their early funding here, and then move to the United States to commercialise. Do you see that changing, with more companies scaling up in Europe?
We’d like to see that. We’d like to be able to say you can scale up more here in the UK. As investors and company builders, you have to take informed, calculated risks. The first risk is whether the biology works. The second is whether we can run a clinical study. The third is whether a regulator will approve it. And the fourth is, if it gets approved, can we get it to patients and get it reimbursed with a higher degree of certainty?
You could get approval in the UK; the question is whether you’ll also get reimbursement with certainty. We’re not that late-stage investor or late-stage stakeholder, but at a certain point you’re looking for the drug to be launched, and then you’re looking at a different metric. I’m looking at p-values. Other people at that point are looking at dollar values. If you don’t have certainty on the dollar values, you put the whole medicine at risk.
A single FDA approval allows a company to market a medicine across the US, with coverage and reimbursement decided separately. In Europe, pricing and reimbursement are generally handled country by country, which can affect where and when companies launch.
That’s part of the system. What we can do better is make people see the value in launching, or accelerating launch and access to medicines, in the UK and Europe. That is something that will hopefully improve in time.
4BIO’s portfolio has a strong social impact dimension. Why does that matter, and why should the wider sector pay attention to it?
For me, impact in biotechnology is one of the easiest things to express. There are more than 7,000 rare diseases, and the majority have no approved treatment. With many of these innovative new technologies, we’re using them for the first time to prove they work in small groups of patients where there was nothing in the past.
Hearing about the difference Casgevy can make to everyday life for someone with sickle cell disease brought home what these medicines can mean for patients and their families.
4BIO was an early investor in Orchard Therapeutics, whose work included gene therapy for ADA-SCID. What did that experience teach you?
One of the lessons from that experience — and it’s something that has stuck with me and that I’m still passionate about — is that approval isn’t the end of the journey. We have to help keep treatments available to patients. That matters particularly in ultra-rare diseases, where you can often see a therapy working scientifically while it struggles commercially. I still think that as a sector we have a responsibility to find ways of preserving access in those circumstances, whether through a company, an academic centre, a charity or different financing. There are a lot of bodies set up like that now, and we should try to support them where we can.
With the tools we have available, our opportunities aren’t limited to rare paediatric diseases. In diseases like Huntington’s, sickle cell and haemophilia, we’re now able to understand the underlying biology and actually alter the course of a patient’s life.
When I think about impact, I don’t really think about ESG labels. For me, it’s about whether a medicine ultimately creates a benefit and changes what’s possible for someone in their life. With every therapy we invest in, we ask: what is the unmet technical need, and what is the unmet clinical need? Not every idea will get there, but with all the ideas we have that are continuing, we know we’re really moving the needle for patients.
The social impact is huge, both for the patients who get the drug and for their families, who don’t have to give up work or commit time and travel to caring for them. It gives me that warm and fuzzy feeling. I’m not in the lab — at times I wish I still was — but I see the social impact day to day, when data cuts come in from portfolio companies and you can see some of these drugs really working and changing people’s lives.
What kinds of companies have you worked with as an investor?
I’ve worked with early-stage Biotechs for the entire time I’ve been in venture — UK, Europe and the US, from formation through to clinical proof of concept. I think I’m on seven boards now, ranging from phase 2 ophthalmology and oncology companies to preclinical renal and neurology companies, with modalities including gene therapy, cell therapy, degraders, non-viral medicines and bispecifics. It’s a plethora of excitement, and every day is different. I can’t complain.
That’s a very diverse portfolio. How closely do you work with the companies you back?
My passions are ophthalmology and oncology. Fortunately, you spend a lot of time working with people, so you learn a lot and, working the way we do as a group, you can be somewhat additive. We’re a hands-on investor. We work very closely with our CEOs, spend time with them on a weekly basis, and like to help form business strategy — but also to make the right decisions early, when you can make some really bad ones that can’t be reversed easily.
Building a company is rarely smooth. When the first serious difficulties arrive, what keeps founders going rather than giving up?
As an investor, this one’s easier for me. It’s very easy to give up when you don’t believe in the technology, and a lot of people will. But if you have a clear sense of why you’re doing what you’re doing — usually anchored in conviction in the technology, and also a commitment to a particular group of patients — that keeps people going when the evidence is there. I seldom see a scientific team back down. When the evidence is a little mixed, things can be more challenging.
Founders do need people around them who will challenge them rather than simply say yes, and that’s often the job of the other co-founders, the board and the investors. But I’ll stick to my point: persistence is usually driven by evidence. Persistence not driven by evidence can make for some uncomfortable discussions.
Finally, how do you find and choose the next company to back?
We’ve been around for a while. And, as I said, there are fewer and fewer early-stage investors. Others investing less early has meant that we do get fantastic deals. People reach out to us directly by email, or they see us at conferences, which we make a point of attending as a group. We’re introduced by other venture groups and by pharma companies. We are present, we are constant, we are consistent, so we get good direct deal flow. Some investments are de novo creations, where we’ve engaged with a number of academics and built the company internally.
We benefit from still being here, which is a good thing, but we also have a very good reputation and brand for consistently building high-quality biotechs. Several of the companies we’ve helped form have gone on to raise substantial Series A rounds.
We’ve been quite successful in the past, and people want to keep working with us.
I don’t often get this opportunity, so: I was on a panel about three weeks ago, and somebody said, ‘We’re all still here.’ It made me think of the Welsh phrase ‘Yma o Hyd’, which literally translates as ‘still here’.






